BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kundra A, Wang JC. Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. Crit Rev Oncol Hematol. 2017;112:103-112. [PMID: 28325251 DOI: 10.1016/j.critrevonc.2017.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Jia H, Thelwell C, Dilger P, Bird C, Daniels S, Wadhwa M. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res. 2018;163:105-116. [PMID: 29407621 DOI: 10.1016/j.thromres.2018.01.039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
2 Syed U, Wahlberg KJ, Douce DR, Sprague JR. Thrombotic Thrombocytopenic Purpura Associated with Pazopanib. Case Rep Hematol 2018;2018:4327904. [PMID: 30057830 DOI: 10.1155/2018/4327904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Saly DL, Perazella MA. The adverse kidney effects of cancer immunotherapies. Journal of Onco-Nephrology 2018;2:56-68. [DOI: 10.1177/2399369318808806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Santoriello D, Husain SA, De Serres SA, Bomback AS, Crew RJ, Vasilescu ER, Serban G, Campenot ES, Kiryluk K, Mohan S, Hawkins GA, Hicks PJ, Cohen DJ, Radhakrishnan J, Stokes MB, Markowitz GS, Freedman BI, D'Agati VD, Batal I. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Kidney Int 2018;94:1189-98. [PMID: 30287079 DOI: 10.1016/j.kint.2018.06.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
5 Dauvergne M, Buob D, Rafat C, Hennino MF, Lemoine M, Audard V, Chauveau D, Ribes D, Cornec-Le Gall E, Daugas E, Pillebout E, Vuiblet V, Boffa JJ; French Nephropathology Group. Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review. Clin Kidney J 2021;14:2563-72. [PMID: 34950468 DOI: 10.1093/ckj/sfab114] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Scully M. Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy. Hematology Am Soc Hematol Educ Program 2017;2017:651-9. [PMID: 29222317 DOI: 10.1182/asheducation-2017.1.651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gianassi I, Allinovi M, Caroti L, Cirami LC. Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature. World J Nephrol 2019; 8(7): 109-117 [PMID: 31750091 DOI: 10.5527/wjn.v8.i7.109] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Cervantes CE, Kant S, Atta MG. The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy. Drug Metab Lett 2021;14:97-105. [PMID: 34279209 DOI: 10.2174/1872312814666210716141633] [Reference Citation Analysis]
9 Iacopo G, Allinovi M, Caroti L, Cirami LC. Broad spectrum of interferon-related nephropathies—glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature. WJN 2019;8:109-17. [DOI: 10.5527/wjgo.v8.i7.109] [Reference Citation Analysis]
10 Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 2020;4:1166-77. [PMID: 32208488 DOI: 10.1182/bloodadvances.2020001515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
11 Kamal A, Hafez Youssef A, Refaat Mansour A. Acute Hepatitis Caused by Genotype 4 HCV Presenting with Microangiopathic Hemolytic Anemia. ACG Case Rep J 2018;5:e73. [PMID: 30370312 DOI: 10.14309/crj.2018.73] [Reference Citation Analysis]
12 Gloude NJ, Dandoy CE, Davies SM, Myers KC, Jordan MB, Marsh RA, Kumar A, Bleesing J, Teusink-Cross A, Jodele S. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. J Clin Immunol 2020;40:699-707. [PMID: 32447592 DOI: 10.1007/s10875-020-00789-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
13 Perazella MA, Shirali AC. Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. J Am Soc Nephrol 2018;29:2039-52. [PMID: 29959196 DOI: 10.1681/ASN.2018050488] [Cited by in Crossref: 67] [Cited by in F6Publishing: 36] [Article Influence: 16.8] [Reference Citation Analysis]
14 Omoto S, Utsumi T, Matsuno H, Terasawa Y, Iguchi Y. Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis. Intern Med 2018;57:741-4. [PMID: 29151517 DOI: 10.2169/internalmedicine.9326-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]